The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지

CD4O Activation Protects Dendritic Cells from Anticancer Drug-Induced Apoptosis

  • Jun, Jae-Yeon (Department of Veterinary Medicine, Cheju Notional University) ;
  • Joo, Hong-Gu (Department of Veterinary Medicine, Cheju Notional University)
  • Published : 2003.10.21
Download PDF
⟨ Previous Next ⟩

Abstract

Dendritic cells (DCs) play a critical role in various immune responses involving $CD4^+$ T cells and have been used to generate anti-tumor immunity. Chemotherapy induces severe side effects including immunosuppression in patients with cancer. Although immunosuppression has been studied, the effects of anticancer drugs on DCs are not fully determined. In this study, we demonstrated that CD40 activation strongly protected DCs from 5-fluorouracil (5-FU) or mitomycin C-induced apoptosis. DCspecific surface markers, including CD11c and major histocompatibility complex (MHC) class II, were used for identifying DCs. CD 40 activation with anti-CD40 mAb significantly enhanced the viability of DCs treated with 5-FU or mitomycin C, assayed by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide). Fluorescence staining and analysis clearly confirmed the enhancing effect of anti-CD40 mAb on the viability of DCs, suggesting that CD40 activation may transduce critical signals for the viability of DCs. Annexin V staining assay showed that CD40 significantly protected DCs from 5-FU or mitomycin C-induced apoptosis. Taken together, this study shows that CD40 activation with anti-CD40 mAb has strong anti-apoptosis effect on DCs, suggesting that CD40 activation may overcome the immunosuppression, especially downregulation of number and function of DCs in chemotherapy-treated cancer patients.

Keywords

References

  1. Aicher A, Shu GL, Magaletti D, Mulvania T, Pezzutto A, Craxton A, Clark EA. Differential role for p38 mitogen-activated protein kinase in regulating CD40-induced gene expression in dendritic cells and B cells. J Immunol 163: 5786 5795, 1999
  2. Ardeshna KM, Pizzey AR, Devereux S, Khwaja A. The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide- stimulated human monocyte-derived dendritic cells. Blood 96: 1039 1046, 2000
  3. Arrighi JF, Rebsamen M, Rousset F, Kindler V, Hauser C. A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers. J Immunol 166: 3837 3845, 2001 https://doi.org/10.4049/jimmunol.166.6.3837
  4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392: 245 252, 1998 https://doi.org/10.1038/32588
  5. DeKernion JB. The chemotherapy of advanced bladder carcinoma. Cancer Res 37: 2771 2774, 1977
  6. Garewal HS. Mitomycin C in the chemotherapy of advanced breast cancer. Semin Oncol 15: 74 79, 1988
  7. Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, Taidi B, Engleman EG, Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritc cells. Nature Medicine 2: 52 58, 1996 https://doi.org/10.1038/nm0196-52
  8. Inaba K, Inaba M, Romani N, Aya H, Deguchi M, Ikehara S, Muramatsu S, Steinman RM. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176: 1693 1702, 1992 https://doi.org/10.1084/jem.176.6.1693
  9. Kanto T, Kalinski P, Hunter OC, Lotze MT, Amoscato AA. Ceramide mediates tumor-induced dendritic cell apoptosis. J Immunol 167: 3773 3784, 2001 https://doi.org/10.4049/jimmunol.167.7.3773
  10. Keane TE, Gingrich JR, Rosner G, Webb KS, Poulton SH, Walther PJ. Combination versus single agent therapy in effecting complete therapeutic response in human bladder cancer: analysis of cisplatin and/or 5-fluorouracil in an in vivo survival model. Cancer Res 54: 475 481, 1994
  11. Labeur MS, Roters B, Pers B, Mehling A, Luger TA, Schwarz T, Grabbe S. Generation of tumor immunity by bone marrowderived dendritic cells correlates with dendritic cell maturation stage. J Immunol 162: 168 175, 1999
  12. Lokshin AE, Kalinski P, Sassi RR, Mailliard RB, Muller-Berghaus J, Storkus WJ, Peng X, Marrangoni AM, Edwards RP, Gorelik E. Differential regulation of maturation and apoptosis of human monocyte-derived dendritic cells mediated by MHC class II. Int Immunol 14: 1027 1037, 2002 https://doi.org/10.1093/intimm/dxf073
  13. Macdonald AG, Nicolson MC, Samuel LM, Hutcheon AW, Ahmed FY. A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site. Br J Cancer 86: 1238 1242, 2002 https://doi.org/10.1038/sj.bjc.6600258
  14. Mackey MF, Gunn JR, Maliszewsky C, Kikutani H, Noelle RJ, Barth RJ Jr. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 161: 2094 2098, 1998
  15. McLellan A, Heldmann M, Terbeck G, Weih F, Linden C, Brocker EB, Leverkus M, Kampgen E. MHC class II and CD40 play opposing roles in dendritic cell survival. Eur J Immunol 30: 2612-2619, 2000. https://doi.org/10.1002/1521-4141(200009)30:9<2612::AID-IMMU2612>3.0.CO;2-G
  16. Mellman I, Steinman RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 106: 255 258, 2001 https://doi.org/10.1016/S0092-8674(01)00449-4
  17. Moertel CG. Clinical management of advanced gastrointestinal cancer. Cancer 36: 675 682, 1975 https://doi.org/10.1002/1097-0142(197508)36:2+<675::AID-CNCR2820360810>3.0.CO;2-A
  18. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Medicine 4: 328 332, 1998 https://doi.org/10.1038/nm0398-328
  19. Shimizu S, Eguchi Y, Kamiike W, Itoh Y, Hasegawa J, Yamabe K, Otsuki Y, Matsuda H, Tsujimoto Y. Induction of apoptosis as well as necrosis by hypoxia and predominant prevention of apoptosis by Bcl-2 and Bcl-XL. Cancer Res 56: 2161 2166, 1996
  20. Smith FP, Hoth DF, Levin B, Karlin DA, MacDonald JS, Woolley PV 3rd, Schein PS. 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 46: 2014 2018, 1980 https://doi.org/10.1002/1097-0142(19801101)46:9<2014::AID-CNCR2820460920>3.0.CO;2-D